Status of Artificial Liver Support: 1977

  • Paul D. Berk


From the title of this symposium and the distribution of papers, one might mistakenly conclude that artificial liver and artificial kidney development were proceeding in parallel. In fact, progress in these two areas is decades apart. Artificial kidney devices are a standard form of therapy which is currently sustaining the lives of more than 20,000 people in the United States alone (1). In contrast, the sum total of all patients in hepatic failure ever treated with any experimental hepatic support device appears to be approximately 200. Moreover, analysis of the available data on the minority of survivors leaves uncertain the extent to which the devices employed contributed to their recovery.


Hepatic Encephalopathy Hepatic Failure Fulminant Hepatic Failure Hepatic Coma Acute Hepatic Failure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Burton, B. T.: Overview and state of the art. In Proceedings of the 9th Annual Contractors Conference of the Artificial Kidney Program of the National Institute of Arthritis, Metabolism and Digestive Diseases, DHEW Publication No. (NIH) 77–1167, U. S. Department of Health, Education and Welfare, Washington, 1967, pp. 188–192.Google Scholar
  2. 2.
    Klebba, A. J., Maurer, J. D., Glass, E. J.: Mortality trends for leading causes of death: United States, 1950–1969. National Center for Health Statistics: Data from the National Vital Statistics System, Series 20, No. 16, U. S. Department of Health, Education and Welfare Publication No. (HRA) 74–1853, U. S. Government Printing Office, Washington, 1974.Google Scholar
  3. 3.
    Maher, J. F., Nolph, K. D., Bryan, C. W.: Prognosis of advanced chronic renal failure. Ann. Intern. Med. 81:43–47, 1974.PubMedGoogle Scholar
  4. 4.
    Trey, C.: The fulminant hepatic failure surveillance study. Brief review of the effects of presumed etiology and age on survival. Can. Med. Assoc. J. 106:525–527, 1972.PubMedGoogle Scholar
  5. 5.
    Berk, P. D., Martin, J. F., Scharschmidt, B. F., Plotz, P. H.: Current status of artificial hepatic support systems. In Progress in Liver Diseases, Volume V, Chapter 24, H. Popper and F. Schaffner (Editors), Grune and Stratton, New York, 1976, pp. 398–417.Google Scholar
  6. 6.
    Gazzard, B. G., Portmann, B., Murray-Lyon, I. M., Williams, R.: Causes of death in fulminant hepatic failure and relationship to quantitative histological assessment of parenchymal damage. Quart. J. Med. 44:615–626, 1975.PubMedGoogle Scholar
  7. 7.
    Geiger, A.: Correlation of brain metabolism and function by the use of a brain perfusion method in. Situ. Physiol. Rev. 38:1–20, 1958.Google Scholar
  8. 8.
    Opolon, P., Huguet, C., Granger, A., Gallot, D., Bloch, P., Bidallier, M.: Comparison of single and cross hemodialysis with a donor through cuprophan and a new polymer membrane. In Artificial Hepatic Support, R. Williams and I. M. Murray-Lyon (Editors), Pitman, London, 1975, pp. 186–201.Google Scholar
  9. 9.
    Roche-Sicot, J., Sicot, C., Peignoux, M., Bourdiau, D., Degos, F., Degos J-D., Prondi, D., Rueff, B., Benhamou, J-P.: Acute hepatic encephalopathy in the rat: The effect of cross circulation. Clin. Sci. Mol. Med. 47:609–615, 1974.PubMedGoogle Scholar
  10. 10.
    Zieve, L.: Metabolic abnormalities in hepatic coma and potential toxins to be removed. In Artificial Hepatic Support, R. Williams and I. M. Murray-Lyon (Editors), Pitman, London, 1975, pp. 11–26.Google Scholar
  11. 11.
    Schenker, S., Breen, K. J., Hoyumpa, A. M. Jr.: Hepatic encephalopathy: Current status. Gastroenterology66:121–154, 1974.PubMedGoogle Scholar
  12. 12.
    Zieve, L., Nicoloff, D. M.: Pathogenesis of hepatic coma. Ann. Rev. Med. 26:143–157, 1975.PubMedCrossRefGoogle Scholar
  13. 13.
    Zieve, L., Doizaki, W., Zieve, F. J.. Synergism between mercaptans and ammonia or fatty acids in the production of coma: A possible role for mercaptans in the pathogenesis of hepatic coma. J. Lab. Clin. Med. 83:16–28, 1974.PubMedGoogle Scholar
  14. 14.
    Zieve, F. J., Zieve, L., Doizaki, W. M., Gilsdorf, R. B.: Synergism between ammonia and fatty acids in the production of coma: Implications for hepatic coma. J. Pharmacol. Exp. Ther. 191: 10–16, 1974.PubMedGoogle Scholar
  15. 15.
    Kiley, J. E., Pender, J. C., Welch, H. F., Welch, C.S.: Ammonia intoxication treated by hemodialysis. N. Engl. J. Med. 259:1156–1161, 1958.PubMedCrossRefGoogle Scholar
  16. 16.
    Opolon, P., Rapin, J-R., Huguet, C., Granger, A., Delorme, M-L., Boschat, M., Sausse, A.: Hepatic failure coma treated by polyacrylonitrile membrane hemodialysis. Trans. Amer. Soc. Artif. Int. Organs22:701–710, 1976.Google Scholar
  17. 17.
    Silk, D. B. A., Chase, R. A., Hanid, M. A., Davies, M., Trewby, P. N., Williams, R.: Haemodialysis using the RP6 membrane in fulminant hepatic failure and its effects on amino acid levels. Abstracts of the 23rd Annual Meeting, Amer. Soc. Artif. Int. Organs 6:80, 1977.Google Scholar
  18. 18.
    Chang, T. M. S., Migchelsen, M.: Characterization of possible “toxic” metabolites in uremia and hepatic coma based on the clearance spectrum for larger molecules by the ACAC microcapsule artificial kidney. Trans. Amer. Soc. Artif. Int. Organs 17:246–252, 1973.Google Scholar
  19. 19.
    Gazzard, B. G., Weston, M. J., Murray-Lyon, I. M., Flax, H., Record, C. O., Portman, B., Langley, P. G., Dunlop, E. H., Mellon, P. J., Ward, M. B., Williams, R.: Charcoal hemoperfusion in the treatment of fulminant hepatic failure. Lancet 1:1301–1307, 1974.PubMedCrossRefGoogle Scholar
  20. 20.
    Juggi, J. S.: Extracorporeal cation exchange circuits in the treatment of hyperammonia of liver failure. Med. J. Aust. 1:926–930, 1973.PubMedGoogle Scholar
  21. 21.
    Lopukhin, U. M., Shurkalin, B. K., Leykin, U. A., Evseev, N. G., Molodenkov, M. N., Kuznetzov, V. N., Gorchakov, V. D., Blagosklonov, A. S.: Bilirubin removal by anion exchange resin (Letter). Lancet 2: 461, 1975.PubMedCrossRefGoogle Scholar
  22. 22.
    Rosenbaum, J. L., Kramer, M. S., Raja, R., Boreyko, C.: Resin hemoperfusion: A new treatment for acute drug intoxication. N. Engl. J. Med. 284:874–877, 1971.PubMedCrossRefGoogle Scholar
  23. 23.
    Gazzard, B. G., Buxton, B. H., Winch, J., Machado, A. L., Flax, H., Williams, R.: Effects of haemoperfusion through charcoal or XAD-2 resin on an animal model of fulminant hepatic failure. Gut 15:482–486, 1974.PubMedCrossRefGoogle Scholar
  24. 24.
    Scharschmidt, B. F., Plotz, P. H., Berk, P. D., Waggoner, J. G., Vergalla, J.: Removing substances from blood by affinity chromatography. II. Removing bilirubin from the blood of jaundiced rats by hemoperfusion over albumin-conjugated agarose beads. J. Clin. Invest. 52:786–795, 1974.CrossRefGoogle Scholar
  25. 25.
    Scharschmidt, B. F., Martin, J. F., Shapiro, L. J., Plotz, P. H., Berk, P. D.: Hemoperfusion through albumin-agarose gel for the treatment of neonatal jaundice in premature Rhesus monkeys. J. Lab. Clin. Med. 89:101–109, 1977.Google Scholar
  26. 26.
    Denti, E., Luboz, M. P.: Preparation and properties of gel-entrapped liver cell microsomes. In Artificial Liver Support, R. Williams and I. M. Murray-Lyon (Editors), Pitman, London, 1975, pp. 148–152.Google Scholar
  27. 27.
    Brunner, G., Jaworek, D.: A new approach towards an extracorporeal management of liver failure: The use of detoxifying enzymes bound to artificial membranes. Abstracts of the VI Meeting of the International Association for the Study of the Liver, Acapulco, October 20–24, 1974.Google Scholar
  28. 28.
    Wolf, C. F. W., Munkelt, B. F.: Bilirubin conjugation by an artificial liver composed of cultured cells and synthetic capillaries. Trans. Amer. Soc. Artif. Int. Organs 28:16–27, 1975.Google Scholar
  29. 29.
    Bruck, S. D.: Blood compatible materials for extracorporeal assist and related devices. In Artificial Hepatic Support, R. Williams and I. M. Murray-Lyon (Editors), Pitman, London, 1975, pp. 68–82.Google Scholar
  30. 30.
    Walker, J. M., Denti, E., Van Wagenen, R., Andrade, J. D.: Evaluation and selection of activated carbon for hemoperfusion. Kidney International 10:S320–S327, 1976.Google Scholar
  31. 31.
    Scharschmidt, B. F., Martin, J. F., Shapiro, L. J., Plotz, P. H., Berk, P. D.: The use of calcium chelating agents and prostaglandin E1 to eliminate platelet and white blood cell losses resulting from hemoperfusion through uncoated charcoal, agarose gel, and neutral and cation exchange resins. J. Lab. Clin. Med. 89:110–119, 1977.PubMedGoogle Scholar
  32. 32.
    Weston, M. J., Mellon, P. J., Langley, P. G., Hughes, R. D., Dunlop, E., H., Gazzard, B. G., Williams, R.: Resin column perfusion with whole blood or plasma separated by the continuous flow celltrifuge. Clin. Sci. Molec. Med. 48:187–192, 1975.Google Scholar
  33. 33.
    Ito, Y., Suaudeau, J., Bowman, R. L.: A new flow-through centrifuge without rotating seals applied to plasmapheresis. Science 189:999–1000, 1975.PubMedCrossRefGoogle Scholar
  34. 34.
    Yamazaki, Z., Fujimori, Y., Sanjo, K., Sigiura, M., Wada, T., Inoue, N., Oda, T., Kominami, N., Fujisaki, U., Hayang, F.: New artificial liver support systems for hepatic coma, Abstracts of the 23rd Annual Meeting, Amer. Soc. Artif. Int. Organs 6:99, 1977.Google Scholar
  35. 35.
    Keynes, W. M.: Hemodialysis in the treatment of liver failure. Lancet 2:1236–1238, 1968.PubMedCrossRefGoogle Scholar
  36. 36.
    Benhamou, J-P., Rueff, B., Sicot, C.: Severe hepatic failure: A critical study of current therapy. In Liver and Drugs, F. Orlandi and A. M. Jezequel (Editors), Academic Press, New York, 1972, pp. 213–228.Google Scholar
  37. 37.
    Gazzard, B. G., Weston, M. J., Murray-Lyon, I. M., Record, C. O., Williams, R.: Experience at King’s College Hospital with charcoal hemoperfusion: Overall results in 37 patients. In Artificial Hepatic Support, R. Williasm and I. M. Murray-Lyon (Editors), Pitman, London, 1975, pp/234–241.Google Scholar
  38. 38.
    Berk, P. D.: A computer simulation study relating to the treatment of fulminant hepatic failure by hemoperfusion. Proc. Soc. Exp. Biol. Med., 1977 (in press).Google Scholar

Copyright information

© Plenum Press, New York 1978

Authors and Affiliations

  • Paul D. Berk
    • 1
  1. 1.Section on Diseases of the Liver, National Institute of Arthritis, Metabolism and Digestive DiseasesNational Institutes of HealthBethesdaUSA

Personalised recommendations